Labor’s FoI backdown is a welcome victory for transparency and accountability

Health Minister Mark Butler has again stepped in to override the direction emerging from a federal advisory committee, abandoning a planned reclassification of intravitreal eye injections after warnings the change could harm patients financially and disrupt access to essential treatment.

New Zealand's Pharmac says a new multiproduct agreement with Roche is delivering benefits for patients and the health system, reducing treatment times and freeing up thousands of infusion hours across hospitals.

Over the past four months, the publication’s archive of more than 16,000 articles, totalling over seven million words, has been transformed into a generative 'beta' large language model. We describe it as a natural language insights platform.

BPDInsights.ai performs best when users ask clear, direct questions, with some specifics and multiple layers. It simply uses these inputs to determine the user's intent.

More than 650 leaders from across Australia’s life sciences community will gather in Sydney to mark International Women’s Day at the Women in Life Sciences Leadership Summit and Luncheon, hosted by AusBiotech and Medicines Australia.

In the current budget year, the Australian government is expected to spend roughly $780 billion. Around $125 billion will go to healthcare. Within this enormous envelope, however, the amount allocated to innovative medicines is vanishingly small. This reflects a choice that is consistently misrepresented as an affordability challenge. Affordability is the consequence of the choice, not a reason.

Wesfarmers Health has opened a major new fulfilment centre in Cairns, marking a significant investment aimed at improving the supply of medicines and health products to communities across Far North and regional Queensland.

Australia will play a key role in protecting Canadians in the event of a future influenza pandemic under a new agreement between CSL Seqirus and the Canadian government.

The list, released by Great Place To Work, identifies employers that combine strong business performance with workplace cultures designed to support women at every stage of their careers.

With just one week remaining in this year’s Rare Cancers Australia Kosi Challenge Pharma Cup, the pharmaceutical industry is helping drive a fundraising surge that is set to push the overall total beyond half a million dollars.

Australia’s rapid expansion of telehealth has transformed how patients access care, but it has also raised an important question about how virtual healthcare providers ensure safety, quality and accountability in a digital environment.

While it is understandable that companies will prioritise large and potentially lucrative markets, surely the correct response from smaller or mid-size markets is to make their settings more attractive? Unless the response is driven by ideology.

PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.

Seven Australian medtech companies are being supported to accelerate their pathway into local procurement through a national capability program aimed at strengthening the adoption of homegrown medical technologies.

Owen Smith, General Manager of Bristol Myers Squibb New Zealand, said, "There was a clear and strong consensus from those consulted that reform is necessary to improve access to medicines in New Zealand to support better outcomes for patients and, over time, help reduce pressure across the wider health system.”

With ten days remaining in this year’s Rare Cancers Australia Kosi Challenge Pharma Cup, the pharmaceutical industry has already demonstrated remarkable momentum, contributing more than $225,000 to the overall fundraising total of $420,000 to date.

In the United States, where the health system maintains a strong structural bias toward rapid access once the regulator approves a therapy, the 44-day outcome translates into virtually immediate insured access for more than 90 per cent of Americans through a mix of private and public coverage.

Australian researchers are set to transform how scientists understand multiple sclerosis by developing a platform that can analyse more than 100 genetic risk factors simultaneously, marking a pivotal step toward more precise treatments and better long-term outcomes.

Australia is paying a steep and largely invisible price for obesity, with a new report funded by Lilly estimating the condition is draining $45 billion from the national economy each year, or about $123 million every day.